113 related articles for article (PubMed ID: 28418923)
1. OSU-A9 inhibits pancreatic cancer cell lines by modulating p38-JAK-STAT3 signaling.
Tsai WC; Bai LY; Chen YJ; Chu PC; Hsu YW; Sargeant AM; Weng JR
Oncotarget; 2017 Apr; 8(17):29233-29246. PubMed ID: 28418923
[TBL] [Abstract][Full Text] [Related]
2. OSU-A9, an indole-3-carbinol derivative, induces cytotoxicity in acute myeloid leukemia through reactive oxygen species-mediated apoptosis.
Bai LY; Weng JR; Chiu CF; Wu CY; Yeh SP; Sargeant AM; Lin PH; Liao YM
Biochem Pharmacol; 2013 Nov; 86(10):1430-40. PubMed ID: 24041743
[TBL] [Abstract][Full Text] [Related]
3. A potent indole-3-carbinol derived antitumor agent with pleiotropic effects on multiple signaling pathways in prostate cancer cells.
Weng JR; Tsai CH; Kulp SK; Wang D; Lin CH; Yang HC; Ma Y; Sargeant A; Chiu CF; Tsai MH; Chen CS
Cancer Res; 2007 Aug; 67(16):7815-24. PubMed ID: 17699787
[TBL] [Abstract][Full Text] [Related]
4. A novel indole-3-carbinol derivative inhibits the growth of human oral squamous cell carcinoma in vitro.
Weng JR; Bai LY; Omar HA; Sargeant AM; Yeh CT; Chen YY; Tsai MH; Chiu CF
Oral Oncol; 2010 Oct; 46(10):748-54. PubMed ID: 20843730
[TBL] [Abstract][Full Text] [Related]
5. Targeting of the Akt-nuclear factor-kappa B signaling network by [1-(4-chloro-3-nitrobenzenesulfonyl)-1H-indol-3-yl]-methanol (OSU-A9), a novel indole-3-carbinol derivative, in a mouse model of hepatocellular carcinoma.
Omar HA; Sargeant AM; Weng JR; Wang D; Kulp SK; Patel T; Chen CS
Mol Pharmacol; 2009 Nov; 76(5):957-68. PubMed ID: 19706731
[TBL] [Abstract][Full Text] [Related]
6. OSU-A9, a potent indole-3-carbinol derivative, suppresses breast tumor growth by targeting the Akt-NF-kappaB pathway and stress response signaling.
Weng JR; Tsai CH; Omar HA; Sargeant AM; Wang D; Kulp SK; Shapiro CL; Chen CS
Carcinogenesis; 2009 Oct; 30(10):1702-9. PubMed ID: 19706645
[TBL] [Abstract][Full Text] [Related]
7. OSU-A9 inhibits angiogenesis in human umbilical vein endothelial cells via disrupting Akt-NF-κB and MAPK signaling pathways.
Omar HA; Arafa el-SA; Salama SA; Arab HH; Wu CH; Weng JR
Toxicol Appl Pharmacol; 2013 Nov; 272(3):616-24. PubMed ID: 23921148
[TBL] [Abstract][Full Text] [Related]
8. OSU-A9 induced-reactive oxygen species cause cytotoxicity in duodenal and gastric cancer cells by decreasing phosphorylated nuclear pyruvate kinase M2 protein levels.
Chiu CF; Weng JR; Lee SL; Wu CY; Chu PC; Shan YS; Yang HR; Bai LY
Biochem Pharmacol; 2020 Apr; 174():113811. PubMed ID: 31954719
[TBL] [Abstract][Full Text] [Related]
9. Sensitization of hepatocellular carcinoma cells to Apo2L/TRAIL by a novel Akt/NF-κB signalling inhibitor.
Omar HA; Arafa el-SA; Maghrabi IA; Weng JR
Basic Clin Pharmacol Toxicol; 2014 Jun; 114(6):464-71. PubMed ID: 24401154
[TBL] [Abstract][Full Text] [Related]
10. Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib.
Nagaraju GP; Mezina A; Shaib WL; Landry J; El-Rayes BF
Eur J Cancer; 2016 Jan; 52():109-19. PubMed ID: 26682870
[TBL] [Abstract][Full Text] [Related]
11. STAT3-targeting RNA interference inhibits pancreatic cancer angiogenesis in vitro and in vivo.
Huang C; Jiang T; Zhu L; Liu J; Cao J; Huang KJ; Qiu ZJ
Int J Oncol; 2011 Jun; 38(6):1637-44. PubMed ID: 21479358
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of β-catenin signaling suppresses pancreatic tumor growth by disrupting nuclear β-catenin/TCF-1 complex: critical role of STAT-3.
Pramanik KC; Fofaria NM; Gupta P; Ranjan A; Kim SH; Srivastava SK
Oncotarget; 2015 May; 6(13):11561-74. PubMed ID: 25869100
[TBL] [Abstract][Full Text] [Related]
13. Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells.
Lin L; Hutzen B; Zuo M; Ball S; Deangelis S; Foust E; Pandit B; Ihnat MA; Shenoy SS; Kulp S; Li PK; Li C; Fuchs J; Lin J
Cancer Res; 2010 Mar; 70(6):2445-54. PubMed ID: 20215512
[TBL] [Abstract][Full Text] [Related]
14. OSU-03012, a novel celecoxib derivative, is cytotoxic to myeloma cells and acts through multiple mechanisms.
Zhang S; Suvannasankha A; Crean CD; White VL; Johnson A; Chen CS; Farag SS
Clin Cancer Res; 2007 Aug; 13(16):4750-8. PubMed ID: 17699852
[TBL] [Abstract][Full Text] [Related]
15. LTP-1, a novel antimitotic agent and Stat3 inhibitor, inhibits human pancreatic carcinomas in vitro and in vivo.
Huang HL; Chao MW; Chen CC; Cheng CC; Chen MC; Lin CF; Liou JP; Teng CM; Pan SL
Sci Rep; 2016 Jun; 6():27794. PubMed ID: 27278358
[TBL] [Abstract][Full Text] [Related]
16. Brassinin inhibits STAT3 signaling pathway through modulation of PIAS-3 and SOCS-3 expression and sensitizes human lung cancer xenograft in nude mice to paclitaxel.
Lee JH; Kim C; Sethi G; Ahn KS
Oncotarget; 2015 Mar; 6(8):6386-405. PubMed ID: 25788267
[TBL] [Abstract][Full Text] [Related]
17. Brusatol inhibits growth and induces apoptosis in pancreatic cancer cells via JNK/p38 MAPK/NF-κb/Stat3/Bcl-2 signaling pathway.
Xiang Y; Ye W; Huang C; Lou B; Zhang J; Yu D; Huang X; Chen B; Zhou M
Biochem Biophys Res Commun; 2017 Jun; 487(4):820-826. PubMed ID: 28455228
[TBL] [Abstract][Full Text] [Related]
18. miR-1181 inhibits invasion and proliferation
Wang J; Guo XJ; Ding YM; Jiang JX
World J Gastroenterol; 2017 Mar; 23(9):1594-1601. PubMed ID: 28321160
[TBL] [Abstract][Full Text] [Related]
19. Bazedoxifene as a Novel GP130 Inhibitor for Pancreatic Cancer Therapy.
Wu X; Cao Y; Xiao H; Li C; Lin J
Mol Cancer Ther; 2016 Nov; 15(11):2609-2619. PubMed ID: 27535971
[TBL] [Abstract][Full Text] [Related]
20. A novel STAT3 inhibitor HO-3867 induces cell apoptosis by reactive oxygen species-dependent endoplasmic reticulum stress in human pancreatic cancer cells.
Hu Y; Zhao C; Zheng H; Lu K; Shi D; Liu Z; Dai X; Zhang Y; Zhang X; Hu W; Liang G
Anticancer Drugs; 2017 Apr; 28(4):392-400. PubMed ID: 28067673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
